Abstract | BACKGROUND:
Ovarian cancer is often diagnosed in advanced stages, when survival is poor. Treatment advances have been made, but are inconsistently implemented. Our purpose was to project the maximum life expectancy gains that could be achieved in women with stage IIIC epithelial ovarian cancer if the implementation of available chemotherapy regimens could be optimized. METHODS: RESULTS: Life expectancy associated with optimized implementation vs. current practice was 76.7 vs. 64.5 months (life expectancy gain = 12.2 months). Providing intraperitoneal + intravenous chemotherapy to all eligible patients was the largest driver of life expectancy gains, due to both the potential benefit conferred by intraperitoneal + intravenous chemotherapy and the proportion of eligible women who do not receive intraperitoneal + intravenous chemotherapy in current practice. CONCLUSION:
|
Authors | Anna P Lietz, Davis T Weaver, Alexander Melamed, Jose Alejandro Rauh-Hain, Jason D Wright, Alexi A Wright, Amy B Knudsen, Pari V Pandharipande |
Journal | PloS one
(PLoS One)
Vol. 14
Issue 9
Pg. e0222828
( 2019)
ISSN: 1932-6203 [Electronic] United States |
PMID | 31539415
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
(administration & dosage)
- Combined Modality Therapy
- Cytoreduction Surgical Procedures
(methods)
- Disease-Free Survival
- Drug Therapy
(methods)
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Ovarian Neoplasms
(drug therapy, surgery)
|